个性化文献订阅>期刊> ACS Medicinal Chemistry Letters
 

Discovery of a Potent, Injectable Inhibitor of Aurora Kinases Based on the Imidazo-[1,2-a]-Pyrazine Core

  作者 YU TAO; TAGAT JAYARAM R; KEREKES ANGELA D; DOLL RONALD J; ZHANG YONGLIAN; XIAO YUSHI; ESPOSITE SARA; BELANGER DAVID B; CURRAN PATRICK J; MANDAL AMIT K; SIDDIQUI M ARSHAD; SHIH NENGYANG; BASSO ANDREA D; LIU MING; GRAY KIMBERLY; TEVAR SEEMA; JONES JENNIFER; LEE SUINING; LIANG LIANZHU; PONERY SAMAD; SMITH ELIZABETH B; HRUZA ALAN; VOIGT JOHANNES; RAMANATHAN LATA; PROSISE WINIFRED; HU MENGWEI  
  选自 期刊  ACS Medicinal Chemistry Letters;  卷期  2010年1-5;  页码  214-218  
  关联知识点  
 

[摘要]The imidazo-[1,2-a]-pyrazine (1) is a dual inhibitor of Aurora kinases A and B with modest cell potency (IC50 = 250 nM) and low solubility (5 mu M). Lead optimization guided by the binding mode led to the acyclic amino alcohol 12k (SCH 1473759), which is a picomolar inhibitor of Aurora kinases (TdF K-d Aur A = 0.02 nM and Aur B = 0.03 nM) with improved cell potency (phos-HH3 inhibition IC50 = 25 nM) and intrinsic aqueous solubility (11.4 mM). It also demonstrated efficacy and target engagement in human tumor xenograft mouse models.

 
      被申请数(0)  
 

[全文传递流程]

一般上传文献全文的时限在1个工作日内